Cure My Disease

Don't miss your cure!

 Log in / Sign up

Quick-blast radiation for prostate cancer shows promise in small pilot study

NCT ID NCT03486821

Disease control Sponsor: University of Kansas Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested a new, shorter radiation schedule (ultra-hypofractionation) in 13 men with early-stage prostate cancer. The goal was to see if this approach causes fewer urinary side effects while still controlling the cancer. Participants had low- to intermediate-risk prostate cancer and were followed for up to 3 years to monitor side effects and cancer progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

13 people

The number who actually took part.

Started

Mar 2018

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ability of participant to sign a written informed consent. * Diagnosed with prostate cancer, T1-T2bN0M0 GS6-7, PSA \< 20 * IPSS score \< 15 (and \< 10 if on medication for benign prostatic hypertrophy such as tamsulosin) at time of enrollment (Appendix 21.4) * Prostate volume (by US, CT or MRI measurement) \< 50 cc at time of enrollment * Androgen deprivation therapy based on clinician judgment is permitted on study * Life expectancy \> 10 years based on clinician's judgment * No other active malignancy * Age ≥ 18 years * Performance Status Eastern Cooperative Oncology Group (ECOG) 0-1 (Appendix 21.5). * Other study-specific criteria: * Men of child-bearing potential must not donate sperm while on this study and for 90 days after their last study treatment. NOTE: Acceptable forms of birth control are listed below: * One Barrier method (cervical cap with spermicide plus male condom; diaphragm with spermicide plus male condom) PLUS * Hormonal method (oral contraceptives, implants, or injections) or an intrauterine device (e.g., Copper-T). Exclusion Criteria: * Current or anticipated use of other investigational agents while participating in this study. * Psychiatric illness/social situations that would limit compliance with study requirements * Prior pelvic radiation therapy * Prior prostatectomy * Inflammatory bowel disease or connective tissue disease requiring medical management

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Early stage prostate cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Financial Stress prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Early stage prostate cancer

Contacts and locations

Locations

  • University of Kansas Medical Center/ Cancer Center

    Kansas City, Kansas, 66190, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.